Evifacotrep

CAS No. 2413739-88-3

Evifacotrep( —— )

Catalog No. M28273 CAS No. 2413739-88-3

Evifacotrep, a short transient receptor potential channel 5 ( TRPC5 ) antagonist (WO2020061162, compound 100), can be used for the research of neurological diseases .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 222 Get Quote
10MG 335 Get Quote
25MG 566 Get Quote
50MG 806 Get Quote
100MG 1098 Get Quote
500MG 2205 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Evifacotrep
  • Note
    Research use only, not for human use.
  • Brief Description
    Evifacotrep, a short transient receptor potential channel 5 ( TRPC5 ) antagonist (WO2020061162, compound 100), can be used for the research of neurological diseases .
  • Description
    Evifacotrep, a short transient receptor potential channel 5 ( TRPC5 ) antagonist (WO2020061162, compound 100), can be used for the research of neurological diseases .(In Vitro):Evifacotrep is a short transient receptor potential channel 5 ( TRPC5 ) antagonist.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    TRP/TRPV Channel
  • Recptor
    Raf|KRAS
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2413739-88-3
  • Formula Weight
    441.77
  • Molecular Formula
    C18H12ClF4N5O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (113.18 mM)
  • SMILES
    O=C1NN=CC(N2Cc3ncnc(Oc(cc4)c(C(F)(F)F)cc4F)c3CC2)=C1Cl
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Huestis MP, et al. Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase Inhibitor. ACS Med Chem Lett. 2021 Apr 21;12(5):791-797.
molnova catalog
related products
  • A 425619

    A 425619 is a potent TRPV1 antagonistsystemic administration of the TRPV1 antagonist, A-425619, reversed the decrease in digging behavior induced by CFA injection, further confirming the role of TRPV1, expressed by knee neurons, in acute inflammatory joint pain.

  • RN-1747

    RN-1747 is a selective transient receptor potential cation channel subfamily V member 4 agonists (EC50: hTRPV4 of 0.77 μM, mTRPV4 of 4.0 μM, and rTRPV4 of 4.1 μM). RN-1747 also antagonizes TRPM8 (IC50: 4 μM).

  • JT010

    JT010 is an effective agonist of TRPA1 (EC50 = 0.65 nM).